

#### NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


# **Single Technology Appraisal**

# Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer ID6138

# **Provisional Stakeholder List**

Consultees	Commentators (no right to submit or appeal)
Company	General
Merck Sharp & Dohme	All Wales Therapeutics and Toxicology
(pembrolizumab)	Centre
	Allied Health Professionals Federation
Patient/carer groups	Board of Community Health Councils in
Black Health Agency	Wales
Cancer Black Care	British National Formulary
Cancer Equality	Care Quality Commission
Cancer 52	Department of Health, Social Services
Eve Appeal	and Public Safety for Northern Ireland
Go Girls	Healthcare Improvement Scotland
Helen Rollason Cancer Charity	<ul> <li>Medicines and Healthcare products</li> </ul>
<ul> <li>Independent Cancer Patients Voice</li> </ul>	Regulatory Agency
Jo's Cervical Cancer Trust	National Association of Primary Care
Macmillan Cancer Support	National Pharmacy Association
Maggie's Centres	NHS Confederation
Marie Curie	Scottish Medicines Consortium
South Asian Health Foundation	Welsh Government
Specialised Healthcare Alliance	Welsh Health Specialised Services
Tenovus Cancer Care	Committee
Wellbeing of Women	Danikla annanatan annan aira
Women's Health Concern	Possible comparator companies
	None
Healthcare professional groups	Relevant research groups
Association of Cancer Physicians	Cochrane Gynaecological Cancer
Association of Surgeons of Great  Britain and Instand	Group
Britain and Ireland	Cochrane UK
British Association of Surgical     Opeology	Genomics England
<ul><li>Oncology</li><li>British Geriatrics Society</li></ul>	Institute of Cancer Research
<ul> <li>British Gynaecological Cancer Society</li> </ul>	MRC Clinical Trials Unit
<ul> <li>British Gyhaecological Cancer Society</li> <li>British Institute of Radiology</li> </ul>	National Institute for Health Research
British Oncology Pharmacy	Pro-Cancer Research Fund
Association	
British Psychosocial Oncology Society	Associated Public Health groups

Provisional stakeholder list for the evaluation of pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer ID6138



Consultees	Commentators (no right to submit or appeal)
<ul> <li>British Society for Clinical Cytology</li> <li>British Society for Colposcopy and Cervical Pathology</li> <li>Cancer Research UK</li> <li>National Forum of Gynaecological Oncology Nurses</li> <li>Royal College of Anaesthetists</li> <li>Royal College of General Practitioners</li> <li>Royal College of Nursing</li> <li>Royal College of Obstetricians &amp; Gynaecologists</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal College of Radiologists</li> <li>Royal College of Surgeons</li> <li>Royal College of Surgeons</li> <li>Royal Society of Medicine</li> <li>Society and College of Radiographers</li> <li>UK Clinical Pharmacy Association</li> <li>UK Oncology Nursing Society</li> </ul> Others <ul> <li>Department of Health and Social Care</li> </ul>	<ul> <li>Public Health Wales</li> <li>UK Health Security Agency</li> </ul>
NHS England	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

## **Definitions:**


# **Consultees**

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

Provisional stakeholder list for the evaluation of pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer ID6138

Issue date: November 2023



All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

# **Commentators**

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.